Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Bernstein analyst William Pickering initiates coverage on Biohaven (NYSE:BHVN) with a Outperform rating and announces Price ...
RBC Capital analyst Leonid Timashev reiterates Biohaven (NYSE:BHVN) with a Outperform and maintains $59 price target.
Cantor Fitzgerald analyst Charles Duncan reiterates Biohaven (NYSE:BHVN) with a Overweight.
- SEC Filing
UBS analyst Ashwani Verma maintains Biohaven (NYSE:BHVN) with a Buy and lowers the price target from $55 to $54.
Cantor Fitzgerald analyst Charles Duncan reiterates Biohaven (NYSE:BHVN) with a Overweight.
Biohaven (NYSE:BHVN) reported quarterly losses of $(3.50) per share which missed the analyst consensus estimate of $(1.77) by 9...
Morgan Stanley analyst Terence Flynn initiates coverage on Biohaven (NYSE:BHVN) with a Overweight rating and announces Price...
